Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04170985 · ClinicalTrials.gov registry record
NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology
A clinical trial, sponsored by Illumina.
- Completed
- Registry status
- 160
- Enrollment target
NCT04170985: Completed study, sponsored by Illumina.
NCT04170985 is a clinical trial that has completed, run by Illumina. The registered enrollment target is 160 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04170985 has completed, sponsored by Illumina.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
Study Summary
Prospective, multi-site, single-arm study to evaluate the diagnostic yield of cWGS in adults with neurological disorders. A single cohort naive of genetic testing will receive standard of care testing for 180 days followed by cWGS. The cohort will be followed for a total of 365 days following enrollment.
Primary Outcome
The number of participants who have a diagnosis in the SOC arm vs the cWGS arm as measured by the test outcome
Interventions
- OTHER clinical Whole Genome Sequencing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2024-01-31 |
What the finished NCT04170985 record still lists
NCT04170985 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which clinical Whole Genome Sequencing is the first listed.
NCT04170985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04170985 about?
NCT04170985 is a clinical study titled "NeuroSeq: A Prospective Trial to Evaluate the Diagnostic Yield of Whole Genome Sequencing (WGS) in Adult Neurology". Prospective, multi-site, single-arm study to evaluate the diagnostic yield of cWGS in adults with neurological disorders. A single cohort naive of genetic testing will receive standard of care testing for 180 days followed by cWGS. The cohort will be followed for a total of 365 days following enroll...
What is the current status of trial NCT04170985?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2019-11-18. Estimated completion is 2024-01-31.
What interventions are being tested in trial NCT04170985?
The interventions under investigation include: clinical Whole Genome Sequencing (OTHER).
Who is sponsoring clinical trial NCT04170985?
This trial is sponsored by Illumina, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI